The post-analytic stage of pharmacogenomic (PGx) testing begins once genotyping is technically valid. It covers everything that turns a genotype into a clinical document and keeps that document trustworthy afterward: variant and haplotype reporting, phenotype inference, the list of affected medications, recommendations, stated limitations, review and sign-out, delivery into the EHR, and the versioning and reanalysis that follow when evidence changes. This article walks through each part for laboratory leaders, medical directors and informatics teams, and ends with a template checklist you can audit your current reports against.
TL;DR
- The post-analytic stage includes observed variants or haplotypes, inferred metabolizer phenotypes, affected medications, recommendations, limitations and decision resources, not only the final PDF.
- A good report template is a controlled document: standardized nomenclature, a defined section order, and no patient-specific dosing instructions.
- Never overwrite an interpretation. Store each version and link it to the original genotype data so earlier clinical decisions remain explainable.
- Define reanalysis triggers in advance (guideline, nomenclature, assay, EHR or knowledge-base changes) and use surveillance to prioritize which cases to review.
- Automation shortens turnaround, but your medical director should keep final approval, with an audit trail.
Table of Contents
- What the post-analytic stage includes
- What a clinically useful PGx report template contains
- Reconciling guidelines without overreaching
- Review, sign-out and the audit trail
- Delivering results into the EHR
- Report versioning: keep every interpretation
- Reanalysis: planning for evidence that moves
- Our perspective
- How SignalPGx supports the post-analytic stage
- FAQ
- Sources
What the post-analytic stage includes
The analytic phase ends when the assay performs as validated and genotype calls are released. From that point the lab owns a different set of risks: wrong phenotype assignment, outdated guidance, a recommendation that overreaches, or a result that never reaches the prescriber's workflow in a usable form.
The ACMG technical standard describes the reported content as variants or haplotypes observed, inferred metabolizer phenotypes, medications that may be affected, recommendations, test limitations and resources for clinical decisions. In practice we group the work into five steps:
- Translation: converting raw genotype data (for example a VCF) into star alleles, diplotypes and phenotypes.
- Interpretation: linking each phenotype to drug guidance from sources such as CPIC, DPWG and FDA labeling.
- Report assembly: populating a controlled template with structured and narrative content.
- Review and sign-out: a qualified reviewer approves the report, with the decision logged.
- Delivery and maintenance: transmission to clinicians and the EHR, then versioning and reanalysis over the life of the result.
The first three are usually where labs invest. Steps four and five are where most long-term liability sits, because a PGx result is a lifelong data point that may be used years after the sample was run. For the translation step in depth, see our guide to moving from genotype to phenotype in clinical PGx reporting.
What a clinically useful PGx report template contains
Searches for report templates tend to return glossy sample reports. What matters for a lab is the content contract behind the layout. ACMG advises that a clinical PGx report include genotype and metabolizer phenotypes, a list of affected medications and a generalized statement on alternative therapies, while patient-specific dosing should not be provided in the report itself. The same standard lists the reference sequence, observed variants or haplotypes and test limitations among the expected elements.
A template checklist
| Section | What it should contain | Why it matters |
|---|---|---|
| Patient and specimen identifiers | Name, DOB, accession, collection and report dates | Traceability to the original sample |
| Result summary | Genes tested, genotype or diplotype, inferred phenotype | Quick scan for the prescriber |
| Affected medications | Drugs with gene-drug associations and the guidance source | Connects phenotype to a clinical decision |
| Recommendations | Therapeutic-management statements with supporting evidence, a general note on alternatives | Keeps the report informative without dictating care |
| Drug interaction caveat | A statement that interacting drugs can alter the phenotype | Prevents false reassurance |
| Methodology and limitations | Alleles tested, variants not detected, reference sequence | Defines what a negative result means |
| Nomenclature and references | HUGO gene names, HGVS variant names, guideline citations | Allows verification and reuse |
| Version and sign-out block | Report version, reviewer, date, reason for amendment | Supports the lifecycle described below |
Two details are easy to miss. First, ACMG recommends HUGO gene names and HGVS nomenclature for variants, so star-allele shorthand should not be the only identifier. Second, international workgroup recommendations advise that test descriptions, including limits on variant detection, be made publicly available through a laboratory website or a registry such as the NIH Genetic Testing Registry. A template that lists limitations clearly but is not published anywhere only meets half of that expectation.
For a section-by-section view of how structured fields can be made machine-readable, our article on FHIR-ready PGx report sections is a practical companion.
Reconciling guidelines without overreaching
The post-analytic stage is also where evidence sources collide. CPIC may grade a gene-drug pair differently from DPWG, and the FDA label may say something else again. A lab that silently picks one source creates an inconsistency that a reviewing pharmacist will eventually find.
The ACMG standard suggests reports include FDA therapeutic-management recommendations with supporting evidence and point to resources such as FDA tables and CPIC guidelines, report genotype and phenotype, state that drug interactions can alter phenotype, and leave medication management to the clinician. The same document notes that the FDA's 2018 warning letter cautioned against claims in genetic test reports that predict drug response without sufficient clinical evidence.
A workable policy has three parts:
- A source hierarchy written down and approved by the medical director, so the same conflict is resolved the same way every time.
- An evidence grade attached to each recommendation. Our piece on PGx evidence grading describes six factors to weigh before turning evidence into prescribing guidance.
- Visible disagreement. When sources differ, say so in the report rather than blending them into one sentence.
Review, sign-out and the audit trail
Automation can assemble a draft in seconds, but a PGx report is a medical document. Sign-out should be a defined step with a named reviewer, not a checkbox. The audit trail should capture which interpretation engine version and evidence snapshot produced the draft, who edited it, who approved it, and when.
Automation has a measurable effect on the work around that step. A 2022 case study at Tan Tock Seng Hospital in Singapore reported that automated clinical PGx workflows reduced report generation time from 30 minutes to 5 minutes. The same coverage notes that end-to-end automation helps limit human errors such as typos in report generation. That is a Singapore hospital result, so treat it as an illustration of direction rather than a benchmark for your own lab.
The time saved should go to clinical review, not to skipping it. If your team is weighing AI-assisted drafting, the sequencing in our guide to shipping CLIA-ready AI in PGx reporting keeps the reviewer in control.
Delivering results into the EHR
A PDF alone does not change prescribing at the point of care. Decision support needs coded values. The Council on Pharmacy Standards describes the flow this way: the LIS generates the final, verified result and an interface engine receives HL7v2 or FHIR data, maps it and routes it to the EHR for result filing and clinical decision support. It also states that standardized formats such as HL7v2 or FHIR are needed so decision support engines can act on coded phenotype values.
Real implementations pair both formats. At UCSF Health, PGx results move through an automated pipeline where structured data support EHR clinical decisions while a PDF report is generated for patient access. A broader review recommends reporting PGx results into the patient's EHR, with clinical decision support where feasible.
Two practical points for your interface team:
- Test both normal and abnormal results. The same standards body suggests pharmacists act as quality assurance reviewers, verifying that both normal and abnormal phenotype results flow correctly from the lab system to the EHR. Labs often validate the abnormal case and forget the normal one.
- Start narrow. Mapping one gene-drug pair end to end exposes most integration problems cheaply. We describe that approach in mapping one gene-drug pair in FHIR first.
Vanderbilt's PREDICT program is the often-cited model. Its informatics layer translated raw genomic data into star alleles and phenotypes, linked phenotypes to clinical guidance and managed updates so historical results could be reinterpreted.
Report versioning: keep every interpretation
Searchers asking about genetic report versioning are usually looking for one rule: do not overwrite. The Council on Pharmacy Standards states that versioning is essential and requires a system that stores multiple interpretations over time, linked to immutable original genotype data. It also argues that overwriting old results is clinically unacceptable because it erases the context of earlier medical decisions.
That gives a clear data model:
- Immutable layer: the genotype calls and assay metadata as originally reported.
- Interpretation layer: each interpretation as a separate, dated version tied to the evidence snapshot and software version used.
- Report layer: each issued report, with its status (original, amended, superseded) and the reason for the change.
A clinician who prescribed under version 1 should always be able to see what version 1 said, and why version 2 differs.
What a version record should hold
- Version number and issue date
- Trigger for the change (new guideline, nomenclature update, assay change, corrected error)
- Which genes and drugs changed
- Reviewer and sign-out date
- Whether the clinician was notified, and how
Reanalysis: planning for evidence that moves
Guidelines, nomenclature and labeling change after your report is issued. Liu and colleagues reported in 2021 that post-analytic maintenance includes reprocessing historical results when nomenclature, expert or regulatory guidelines, assay technology, the EHR or the knowledge base changes, and that content expansion can add new gene-drug interpretations to prior results. Their recommended sequence is to identify affected patients, recompute interpretations, update EHR decision support, and review current medication users for clinician notification.
The PREDICT experience points the same way: decision support has to be anticipatory and adaptable so historical genomic results can be reinterpreted as the literature evolves.
Reanalysis guidance from the interpretation and reporting community adds two disciplines. Laboratories should define reanalysis policies in advance, retain the information needed to reproduce prior interpretations, and use evidence-update surveillance to focus review on the cases most likely to change.
A reanalysis policy skeleton
| Element | Decision your lab should record |
|---|---|
| Triggers | Which source changes start a review (CPIC, DPWG, FDA labeling, nomenclature, assay, EHR) |
| Scope | All reported patients, or only those with affected genes and current medications |
| Prioritization | Actionable changes first, informational changes batched |
| Clinical impact rule | What change counts as a new or amended report versus a silent knowledge-base update |
| Notification | Who tells the ordering clinician, how quickly, and how it is documented |
| Documentation | Version record, reviewer and sign-out for every re-issued result |
Manual tracking of this table across dozens of guideline pages is where most labs fall behind. The failure mode is evidence version drift: two patients with the same genotype receive different advice because one report was built before a guideline update. For a lab that already runs several panels, the drug side of this problem is covered in our drug-gene interaction reference guide.
Our perspective
Most labs we speak with have invested heavily in the analytic phase and treat the report as an export. We see it the other way round. The report is the product your clients actually use, and it is the only part of your service that stays in a patient's chart for years.
That is why we build around three commitments. First, evidence should be fused from multiple authoritative sources and graded, so that a recommendation carries its basis with it. Second, reanalysis should be continuous, with alerts when guidance changes, so your team reviews targeted cases and does not rebuild reports by hand. Third, clinicians stay in control: your medical director reviews and approves, and the audit trail shows exactly what was approved.
White-labeling matters here too. A branded report is more than a logo in the corner: your lab's name is on the interpretation, so the versioning, the sign-out record and the limitations statement all have to hold up under your accreditation. Software should make that discipline easier to keep, not just faster to produce.
— Tarek
How SignalPGx supports the post-analytic stage
SignalPGx is pharmacogenomics reporting software for laboratories. It generates evidence-graded reports from genotype and medication data, supports medical-director review with an audit trail, delivers to providers and patients, integrates with EHRs through HL7/FHIR, and applies living reanalysis as guidelines change. Labs can deploy it as branded, white-label infrastructure; our description of the model is on the White-Label PGx Reporting page, which lists the Pilot, Standard, Scale and Enterprise plans.
If you are still defining scope, our Discovery & Strategy, System Design and Deployment & Integration services are available as one-off projects, with Discovery & Strategy from $7,000 per project. For the operational side of launching, see the lab operator's playbook for launching a PGx service.
FAQ
What is the post-analytic phase in PGx testing?
It is the stage after the validated laboratory result: phenotype inference, drug interpretation, report assembly, review and sign-out, delivery to clinicians and the EHR, and ongoing maintenance. The ACMG standard describes the reported content as variants, phenotypes, affected medications, recommendations, limitations and resources. Maintenance includes versioning and reanalysis.
Should a PGx report include dosing instructions?
ACMG advises reports list affected medications and a general statement on alternatives, but not provide patient-specific dosing. Reports should point to resources such as CPIC guidelines and FDA tables, and leave medication management to the treating clinician.
How should labs version PGx reports?
Keep every interpretation as a separate dated version, linked to the original, unchanged genotype data. The Council on Pharmacy Standards says a system must store multiple interpretations over time and that overwriting results is unacceptable. Record the trigger, the reviewer and the notification for each change.
When should a lab reanalyze previously reported PGx results?
Plan reanalysis for changes in nomenclature, guidelines, assay technology, the EHR or the knowledge base, as reported by Liu and colleagues. Decide the triggers and scope in a written policy, then prioritize cases most likely to change, such as patients currently taking affected drugs.
Sources
- Clinical pharmacogenomic testing and reporting: a technical standard (ACMG)
- Impact of Updating Pharmacogenetic Results: Lessons Learned
- 15.4 Variant Re-Interpretation and Version Control
- 15.2 EHR Integration and Data Exchange
- A Tutorial for Pharmacogenomics Implementation Through End-to-End Clinical Decision Support
- Best practices for the interpretation and reporting of clinical genomic reanalysis
- Clinical implementation of preemptive pharmacogenomics at UCSF Health
- Pharmacogenomics in practice: a review and implementation guide
- Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations
- Maximizing Time Efficiencies with an End-to-End Automated Clinical Workflow for Pharmacogenomics Testing